Takeda Targets Severe Epilepsies In Ovid Alliance

Takeda is continuing apace with smaller targeted alliances despite its big Ariad acquisition, this time linking with a private US venture for the global development of a novel drug for serious pediatric epilepsies, in a move that aligns with the Japanese firm's pursuit of R&D externalization.

Dravet Syndrome - Medical Report with Composition of Medicaments - Pills, Injections and Syringe

Takeda Pharmaceutical Co. Ltd. is not being distracted from pursuing smaller specialized deals despite its planned $5.2bn acquisition of US oncology firm Ariad Pharmaceuticals Inc., this time linking up with a small US company to address serious forms of childhood epilepsy.

A new alliance with privately held Ovid Therapeutics Inc. for the global development and commercialization of a novel Takeda...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip